Mittal et al. demonstrated that higher ADORA2B gene expression levels correlate with poorer overall survival in a triple-negative breast cancer subset, but not in luminal A, B, or HER2+ subsets [7]. Here, ADORA2B is linked to triple-negative breast carcinoma.